Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

123.34 USD +1.06 (+0.87%)
Official Closing Price Updated: 6:07 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”)... 
From GlobeNewswire News Releases
Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) partner Retrophin, Inc. today announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental... 
From Business Wire News Releases
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND). Investors, who purchased or... 
From Business Wire News Releases
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who acquired... 
From Business Wire News Releases
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible... 
From Business Wire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:... 
From PR Newswire
INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND).... 
From Business Wire News Releases
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND
Rosen Law Firm Representing Ligand Pharmaceuticals Incorporated Shareholders in Securities Class Action Lawsuit Seeking to Recover Investor Losses - LGND 
From Business Wire News Releases
INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible violations of federal... 
From Business Wire News Releases
LIGAND PHARMACEUTICALS INVESTOR ALERT: Hagens Berman is Investigating Ligand Pharmaceuticals' Accounting Restatements and Possible Securities Law Violations
Hagens Berman Sobol Shapiro LLP alerts investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to the firm's investigation into improper accounting and possible securities law violations. 
From PR Newswire
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible... 
From Business Wire News Releases
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ligand Pharmaceuticals Incorporated
Rosen Law Firm Investigating Potential Securities Claims Against Ligand Pharmaceuticals Incorporated - LGND 
From Business Wire News Releases
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible violations... 
From Business Wire News Releases
Ligand Pharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Announcing Restatement Of Financial Results
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and certain of its officers... 
From PR Newswire
SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible violations of federal... 
From Business Wire News Releases
Harwood Feffer LLP Announces Investigation of Ligand Pharmaceuticals Incorporated
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND), concerning whether... 
From PR Newswire
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND).... 
From PR Newswire
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible... 
From Business Wire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ligand Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Ligand Pharmaceuticals, Inc. concerning possible violations of federal securities laws 
From Business Wire News Releases
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ligand Pharmaceuticals Incorporated and Advises Investors with Losses to Contact the Firm
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (Nasdaq: LGND) concerning possible violations... 
From Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ligand Pharmaceuticals, Inc. - LGND
Pomerantz LLP is investigating claims on behalf of investors of Ligand Pharmaceuticals, Inc. ("Ligand" or the "Company") (NASDAQ: LGND) (ISIN: US53220K5048). Investors are advised to contact Robert S.... 
From PR Newswire
Ligand Reports Third Quarter 2016 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2016, and provided an operating forecast and program updates.... 
From Business Wire News Releases
Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has... 
From Business Wire News Releases
Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2016 financial results on November 3, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and... 
From Business Wire News Releases
Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved Carnexiv™ (carbamazepine) injection as a short-term... 
From Business Wire News Releases
Ligand Licenses Four Programs to Seelos Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the licensing of rights to four programs to Seelos Therapeutics, Inc., a newly formed biopharmaceutical company focused on central nervous... 
From Business Wire News Releases
Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc. Under the license, TeneoBio will be able to use... 
From Business Wire News Releases
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes... 
From Business Wire News Releases
Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Retrophin, Inc. (NASDAQ: RTRX) today announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal... 
From Business Wire News Releases
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 
From Business Wire News Releases
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.